These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10232372)

  • 21. Monocyte-derived dendritic cells from chronic myeloid leukaemia have abnormal maturation and cytoskeletal function that is associated with defective localisation and signalling by normal ABL1 protein.
    Brown S; Hutchinson CV; Aspinall-O'Dea M; Whetton AD; Johnson SM; Rees-Unwin K; Burthem J
    Eur J Haematol; 2014 Aug; 93(2):96-102. PubMed ID: 24617663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
    Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
    Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
    Ly C; Arechiga AF; Melo JV; Walsh CM; Ong ST
    Cancer Res; 2003 Sep; 63(18):5716-22. PubMed ID: 14522890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High affinity molecules disrupting GRB2 protein complexes as a therapeutic strategy for chronic myelogenous leukaemia.
    Feller SM; Tuchscherer G; Voss J
    Leuk Lymphoma; 2003 Mar; 44(3):411-27. PubMed ID: 12688310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
    Simara P; Peterkova M; Stejskal S; Potesilova M; Koutna I; Racil Z; Razga F; Jurcek T; Dvorakova D; Mayer J
    Leuk Lymphoma; 2012 Aug; 53(8):1627-9. PubMed ID: 22233112
    [No Abstract]   [Full Text] [Related]  

  • 26. Differences in tyrosine phosphorylated proteins between cells expressing P210bcr/abl and P190bcr/abl.
    Nishimura J; Shibata K; Sadamura S; Takahira H; Hirata J; Umemura T; Nawata H; Okamura J
    Int J Hematol; 1992 Jun; 55(3):227-33. PubMed ID: 1379843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model.
    Halbach S; Köhler M; Uhl FM; Huber J; Zeiser R; Koschmieder S; Aumann K; Brummer T
    Leukemia; 2016 Sep; 30(9):1942-5. PubMed ID: 27125306
    [No Abstract]   [Full Text] [Related]  

  • 28. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
    Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
    Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
    Shuai K; Halpern J; ten Hoeve J; Rao X; Sawyers CL
    Oncogene; 1996 Jul; 13(2):247-54. PubMed ID: 8710363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients.
    Kardinal C; Konkol B; Schulz A; Posern G; Lin H; Adermann K; Eulitz M; Estrov Z; Talpaz M; Arlinghaus RB; Feller SM
    FASEB J; 2000 Aug; 14(11):1529-38. PubMed ID: 10928987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia.
    Yasuda T; Shirakata M; Iwama A; Ishii A; Ebihara Y; Osawa M; Honda K; Shinohara H; Sudo K; Tsuji K; Nakauchi H; Iwakura Y; Hirai H; Oda H; Yamamoto T; Yamanashi Y
    J Exp Med; 2004 Dec; 200(12):1681-7. PubMed ID: 15611294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction.
    Fahrenkamp D; de Leur HS; Küster A; Chatain N; Müller-Newen G
    Cell Commun Signal; 2015 Feb; 13():10. PubMed ID: 25885255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Mechanism of human leukemogenesis by BCR-ABL].
    Maru Y
    Seikagaku; 1995 May; 67(5):343-55. PubMed ID: 7602207
    [No Abstract]   [Full Text] [Related]  

  • 34. Biology of BCR-ABL.
    Chopra R; Pu QQ; Elefanty AG
    Blood Rev; 1999 Dec; 13(4):211-29. PubMed ID: 10741897
    [No Abstract]   [Full Text] [Related]  

  • 35. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
    Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
    Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular biology of chronic myeloid leukemia.
    Maru Y
    Cancer Sci; 2012 Sep; 103(9):1601-10. PubMed ID: 22632137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Depression of oncogenecity by dephosphorylating and degrading BCR-ABL.
    Gao M; Huang ZL; Tao K; Xiao Q; Wang X; Cao WX; Xu M; Hu J; Feng WL
    Oncotarget; 2017 Jan; 8(2):3304-3314. PubMed ID: 27926512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation.
    Wilson-Rawls J; Xie S; Liu J; Laneuville P; Arlinghaus RB
    Cancer Res; 1996 Aug; 56(15):3426-30. PubMed ID: 8758906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic myeloid leukemia--advances in biology and new approaches to treatment.
    Goldman JM; Melo JV
    N Engl J Med; 2003 Oct; 349(15):1451-64. PubMed ID: 14534339
    [No Abstract]   [Full Text] [Related]  

  • 40. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
    Okuda K; Golub TR; Gilliland DG; Griffin JD
    Oncogene; 1996 Sep; 13(6):1147-52. PubMed ID: 8808688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.